Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CRMD
$7.2549
$
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Next Earnings
2026-02-25
Beta
1.298
Average Volume
Market Cap
Last Dividend
CIK
0001410098
ISIN
US21900C3088
CUSIP
21900C308
CEO
Joseph Todisco
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
64
IPO Date
2010-05-13
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? | CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise. | Zacks Investment Research | 2026-02-24 09:06:07 |
| Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings? | CorMedix heads into Q4 earnings with DefenCath sales, Melinta product contributions, and its muted 2026 guidance firmly in focus. | Zacks Investment Research | 2026-02-23 11:45:25 |
| Principal Financial Group Inc. Invests $1.01 Million in CorMedix Inc $CRMD | Principal Financial Group Inc. bought a new stake in shares of CorMedix Inc (NASDAQ: CRMD) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 86,437 shares of the company's stock, valued at approximately $1,005,000. Principal Financial Group Inc. owned about 0.11% of CorMedix at the | Defense World | 2026-02-19 03:26:48 |
| CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock? | CRMD stock sinks 27% in 3 months as its bearish 2026 outlook for DefenCath clouds near-term growth, raising investor concern. | Zacks Investment Research | 2026-02-17 11:30:38 |
| CorMedix Inc. (CRMD) Analyst/Investor Day Transcript | CorMedix Inc. (CRMD) Analyst/Investor Day Transcript | Seeking Alpha | 2026-02-14 02:37:45 |
| CorMedix to Participate in Upcoming Investor Conferences | BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in March. | GlobeNewsWire | 2026-02-12 08:30:00 |
| CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside | CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products. | Zacks Investment Research | 2026-02-11 09:06:13 |
| CorMedix (NASDAQ:CRMD) to Buyback $75.00 million in Outstanding Stock | CorMedix (NASDAQ: CRMD - Get Free Report) declared that its board has initiated a stock repurchase plan on Monday, February 2nd, RTT News reports. The company plans to repurchase $75.00 million in shares. This repurchase authorization permits the company to repurchase up to 12.3% of its stock through open market purchases. Stock repurchase plans are generally | Defense World | 2026-02-03 01:02:42 |
| CorMedix Therapeutics Announces Share Repurchase Program | BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company's outstanding common stock. | GlobeNewsWire | 2026-02-02 08:30:00 |
| CRMD Down 31% in a Month: Is This an Indication to Sell the Stock? | CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment. | Zacks Investment Research | 2026-01-30 09:40:29 |
| CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 | BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will host an in-person and virtual analyst day in New York on Tuesday, February 10, 2026 with presentations and panels from 1:00 PM to 3:00 PM Eastern. | GlobeNewsWire | 2026-01-29 08:30:00 |
| Hussman Strategic Advisors Inc. Purchases 252,000 Shares of CorMedix Inc $CRMD | Hussman Strategic Advisors Inc. increased its position in CorMedix Inc (NASDAQ: CRMD) by 400.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 315,000 shares of the company's stock after purchasing an additional 252,000 shares during the quarter. CorMedix makes up 0.8% | Defense World | 2026-01-28 05:51:04 |
| Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption? | CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption. | Zacks Investment Research | 2026-01-23 12:01:15 |
| CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? | CRMD and MIRM are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth. | Zacks Investment Research | 2026-01-20 10:40:31 |
| High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 | Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key predictions about trial outcomes. Alongside the continued proliferation of technology within the drug development space, companies with a focus on obesity, rare diseases, and oncology applications saw commercial achievements. | MarketBeat | 2026-01-19 11:28:36 |
| Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings? | CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues. | Zacks Investment Research | 2026-01-15 09:40:47 |
| Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation | New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into CorMedix Inc. ("CorMedix Inc.") (NASDAQ: CRMD) concerning potential violations of the federal securities laws. On January 8, 2026, before the market opened, CorMedix published preliminary fourth quarter and full year 2025 results disclosing that its major revenue driver DefenCath would change its reimbursement policy change beginning on July 1, 2026. | Newsfile Corp | 2026-01-14 09:57:54 |
| CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-13 01:26:00 |
| Are Investors Undervaluing CorMedix (CRMD) Right Now? | Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. | Zacks Investment Research | 2026-01-09 10:40:52 |
| CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that Joseph Todisco, Chairman and CEO of CorMedix Therapeutics, will present a corporate overview at the 44th annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 12, 2026 at 4:30pm PST. | GlobeNewsWire | 2026-01-09 08:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-06 | 2026-02-06 | View Filing |
| 4 | 2026-02-06 | 2026-02-06 | View Filing |
| 4 | 2026-02-06 | 2026-02-06 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-22 | 2026-01-22 | View Filing |
| 4 | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2026-01-15 | 2026-01-15 | View Filing |
| 3 | 2026-01-15 | 2026-01-15 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 8-K | 2026-01-08 | 2026-01-08 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| SC 13G/A | 2026-01-02 | 2026-01-02 | View Filing |
| 4 | 2025-12-19 | 2025-12-19 | View Filing |
| 4 | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-04 | 2025-12-04 | View Filing |
| SC 13G | 2025-12-01 | 2025-12-01 | View Filing |
| 4 | 2025-11-26 | 2025-11-26 | View Filing |
| 4 | 2025-11-18 | 2025-11-18 | View Filing |
| S-8 | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-10-27 | 2025-10-27 | View Filing |
| DEF 14A | 2025-10-24 | 2025-10-24 | View Filing |
| PRER14A | 2025-10-14 | 2025-10-14 | View Filing |
| S-3ASR | 2025-10-07 | 2025-10-07 | View Filing |
| RW | 2025-10-07 | 2025-10-07 | View Filing |
| S-3ASR | 2025-10-06 | 2025-10-03 | View Filing |
| RW | 2025-10-06 | 2025-10-03 | View Filing |
| S-3 | 2025-09-30 | 2025-09-30 | View Filing |
| 8-K/A | 2025-09-30 | 2025-09-30 | View Filing |
| 4 | 2025-09-18 | 2025-09-18 | View Filing |
| 4 | 2025-09-16 | 2025-09-16 | View Filing |
| PRE 14A | 2025-09-15 | 2025-09-15 | View Filing |
| 4 | 2025-09-12 | 2025-09-12 | View Filing |
| 4 | 2025-09-12 | 2025-09-12 | View Filing |
| 3 | 2025-09-12 | 2025-09-12 | View Filing |
| SC 13D | 2025-09-12 | 2025-09-12 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4/A | 2025-09-08 | 2025-09-08 | View Filing |
| 4/A | 2025-09-08 | 2025-09-08 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 3 | 2025-09-03 | 2025-09-03 | View Filing |
| 8-K | 2025-09-02 | 2025-09-02 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| SC 13G/A | 2025-08-08 | 2025-08-08 | View Filing |
| 10-Q | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-06-30 | 2025-06-30 | View Filing |
| 424B5 | 2025-06-30 | 2025-06-30 | View Filing |
| 424B5 | 2025-06-26 | 2025-06-26 | View Filing |
| 8-K | 2025-06-25 | 2025-06-25 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| SC 13G/A | 2025-05-12 | 2025-05-12 | View Filing |
| 10-Q | 2025-05-06 | 2025-05-06 | View Filing |
| 8-K | 2025-05-06 | 2025-05-06 | View Filing |
| ARS | 2025-04-28 | 2025-04-28 | View Filing |
| DEFA14A | 2025-04-28 | 2025-04-28 | View Filing |
| DEF 14A | 2025-04-28 | 2025-04-28 | View Filing |
| 8-K | 2025-04-22 | 2025-04-22 | View Filing |
| 8-K | 2025-04-08 | 2025-04-08 | View Filing |
| SC 13G | 2025-04-04 | 2025-04-04 | View Filing |
| 4 | 2025-04-03 | 2025-04-03 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 10-K | 2025-03-25 | 2025-03-25 | View Filing |
| 8-K | 2025-03-25 | 2025-03-25 | View Filing |
| SC 13G/A | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 8-K | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4/A | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-16 | 2024-12-16 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| ADX | 23.51% | 1 | 408 | 0.06 | 0.21 | 12.46 |
| Neural Forcast | 21.34% | 1 | 976 | 0.02 | 0.03 | 10.3 |
| Momentum Reserve | 19.79% | 1.11 | 60 | 0.04 | 0.12 | 8.75 |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxx | x | xxxx | x |
| xxxxxxxxxx | xxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | x | xxxxx |
| xxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |